Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19

 Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19

Mount Sinai Signs a Multi-Year Collaboration with Harbour BioMed to Develop Novel Biotherapies for Multiple Cancer Indications and COVID-19

Shots:

  • The companies signed a multi-year, multifaceted collaboration to develop novel Ab to treat & prevent various diseases including oncology and immunology
  • The collaboration leverages H2L2 Harbour Mice platform to generate mAb against SARS CoV 2 – COVID-19 and allow HBM to access Mount Sinai’s research-driven from its clinical practices
  • The collaboration demonstrated HBM’s dedication to develop novel therapies and bolster fast-track research. The mAb to be developed in the collaboration have the potential to prevent the spreading of virus by blocking infection of cells

Click here ­to­ read full press release/ article | Ref: Buisnesswire | Image: HBM

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post